dapagliflozin
astrazeneca
['dapagliflozin', 'heart failure', 'farxiga', 'cardio']
use of dapagliflozin (farxiga) was associated with an 18% reduction in worsening hf or cardiovascular death among patients with heart failure with preserved ejection fraction, according to the results of the deliver trial. #heartfailure #hfpef #esc22
Practical Cardiology provides timely reporting and commentary on the science and clinical practice of cardiovascular medicine.